Frecuencia y distribución geográfica del uso de sacubitril/valsartán en Colombia entre los años 2019 y 2020

Frecuencia y distribución geográfica del uso de sacubitril/valsartán en Colombia entre los años 2019 y 2020

Introducción: La adherencia al tratamiento de la falla cardiaca en la vida real es subóptima. Se desconoce la adherencia a las recomendaciones del uso de sacubitril/valsartán en Colombia. Objetivo: Evaluar la frecuencia de uso, la distribución geográfica y las características demográficas de los pac...

Full description

Bibliographic Details
Main Authors:	Nancy Herrera-Leaño, Julián E. Barahona-Correa, Oscar M. Muñoz-Velandia, Daniel G. Fernández-Ávila, Ángel A. García
Format:	Article
Language:	English
Published:	Permanyer 2024-01-01
Series:	Revista Colombiana de Cardiología
Subjects:	Sacubitril/valsartán. Falla cardiaca. Colombia.
Online Access:	https://www.rccardiologia.com/frame_esp.php?id=346

Similar Items

Expert Opinion on the Role of Sacubitril/Valsartan in the Management of Hypertension in India
by: Uday M. Jadhav, et al.
Published: (2024-11-01)

Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
by: David Carballo, et al.
Published: (2020-06-01)

What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies
by: Hisham A. Badreldin, et al.
Published: (2022-02-01)

Impact of Sacubitril/Valsartan on Circulating microRNA in Patients with Heart Failure
by: Maura Brioschi, et al.
Published: (2023-03-01)

Left ventricular output indices and sacubitril/valsartan titration: role of stroke volume index
by: Paolo Tolomeo, et al.
Published: (2022-06-01)

Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats
by: Pema Raj, et al.
Published: (2021-08-01)

Case Series: Sacubitril/Valsartan Role for Chemotherapy-Induced Cardiotoxicity: An in-Depth Investigation in Saudi Arabia
by: Alshammari A, et al.
Published: (2024-01-01)

Long-Term Effects of Sacubitril/Valsartan After Chemotherapy for Breast Cancer in Patients With Chronic heart Failure
by: S. G. Kanorskiy, et al.
Published: (2024-03-01)

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)
by: Ning Wang, et al.
Published: (2024-12-01)

Association between treatment with sacubitril/valsartan and the risk of Alzheimer’s disease: a clinical update
by: Antoine Garnier-Crussard
Published: (2024-08-01)

Effectiveness of Sacubitril/Valsartan in Preventing Heart Failure in STEMI Post-Percutaneous Coronary Intervention
by: Nobian Andre, et al.
Published: (2023-12-01)

Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report
by: Marcely Gimenes Bonatto, et al.
Published: (2020-06-01)

Effects of sacubitril-valsartan in patients undergoing maintenance dialysis
by: Ying Ding, et al.
Published: (2023-12-01)

Sacubitril with valsartan, a modern pharmacotherapy in heart failure - a literature review
by: Bartosz Sadłowski, et al.
Published: (2024-07-01)

Benefits of sacubitril/valsartan administration and physical training in cardiac rehabilitation: current trends and bibliometric analysis of the years 2015-2024
by: Diana Carina Iovanovici, et al.
Published: (2024-06-01)

Sacubitril/valsartan attenuates atrial conduction disturbance and electrophysiological heterogeneity with ameliorating fibrosis in mice
by: Satoshi Iwamiya, et al.
Published: (2024-01-01)

Sex differences and clinical outcomes, including ventricular tachyarrhythmias, of patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
by: Mohammad Abumayyaleh, et al.
Published: (2024-12-01)

A real-world disproportionality analysis of sacubitril/valsartan: data mining of the FDA adverse event reporting system
by: Yiwen Wang, et al.
Published: (2024-08-01)

Sacubitril/Valsartan and Ivabradine Attenuate Left Ventricular Remodelling and Dysfunction in Spontaneously Hypertensive Rats: Different Interactions with the Renin–Angiotensin–Aldosterone System
by: Fedor Simko, et al.
Published: (2022-07-01)

Effect of sacubitril/valsartan on inflammation and oxidative stress in doxorubicin-induced heart failure model in rabbits
by: Yu Chun, et al.
Published: (2021-09-01)

Subgroup disproportionality analysis of dementia-related adverse events with sacubitril/valsartan across geographical regions
by: Seong Kyung Kim, et al.
Published: (2024-09-01)

EFFECT OF SACUBITRIL/VALSARTAN ON NATRIURESIS, DIURESIS AND BLOOD PRESSURE IN HYPERTENSIVE PATIENTS
by: Zh. D. Kobalava, et al.
Published: (2017-07-01)

Detection of muscular system adverse reaction signals in sacubitril/valsartan treatment combined with statins
by: Fukun Zhao, et al.
Published: (2024-07-01)

Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan
by: Jawad H. Butt, et al.
Published: (2024-02-01)

Sacubitril/Valsartan Alleviates Cardiac Remodeling and Dysfunction in L-NAME-Induced Hypertension and Hypertensive Heart Disease
by: Peter Stanko, et al.
Published: (2024-03-01)

Effect of sacubitril/valsartan on lipid metabolism in patients with chronic kidney disease combined with chronic heart failure: a retrospective study
by: Manzhi Li, et al.
Published: (2024-02-01)

Progress in Managing Heart Failure: an in-depth Review of Sacubitril/Valsartan Combination Therapy
by: Neeraj Hiremath, et al.
Published: (2024-04-01)

Sacubitril/Valsartan for Blood Pressure Lowering in Non‐Dialysis‐Dependent Chronic Kidney Disease Stage 3–5 Patients With Hypertension: A Multicenter Clinical Study
by: Yu Yan, et al.
Published: (2025-01-01)

Beneficial Effect of Left Ventricular Remodeling after Early Change of Sacubitril/Valsartan in Patients with Nonischemic Dilated Cardiomyopathy
by: Hyue-Mee Kim, et al.
Published: (2021-04-01)

Retrospective Analysis of Sacubitril/Valsartan vs Benazepril for Treating Heart Failure Following Acute Myocardial Infarction
by: Zhao L, et al.
Published: (2024-12-01)

Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real‐world clinical setting
by: Charlotte Nordberg Backelin, et al.
Published: (2020-06-01)

Natriuretic peptide pathways in heart failure in the context of the analysis of the mechanism of action and potential usages of sacubitril/valsartan
by: Kamila Babkiewicz-Jahn, et al.
Published: (2024-05-01)

Pharmacoutilization and adherence to sacubitril/valsartan in real world: the REAL.IT study in HFrEF
by: Massimo Iacoviello, et al.
Published: (2024-02-01)

Determination of Sacubitril and Valsartan Binary Mixture using Different Eco-friendly Spectrophotometric approaches with or without Regression Equations; greenness and whiteness assessments
by: Ragaa Magdy, et al.
Published: (2023-06-01)

Unlocking the potential of sacubitril/valsartan therapy in improving ECG and echocardiographic parameters in heart failure patients with reduced ejection fraction (HErEF)
by: Lamyaa Elsayed Allam, et al.
Published: (2024-03-01)

Sacubitril/valsartan ameliorates tubulointerstitial fibrosis by restoring mitochondrial homeostasis in diabetic kidney disease
by: Xing-Jian Zhang, et al.
Published: (2024-02-01)

Comparative Study of the Efficacy and Safety of Sacubitril/Valsartan and Dapagliflozin in the Treatment of Dilated Cardiomyopathy with Low Blood Pressure
by: ZHANG Yong, CAI Xiang, NING Feifei, LIANG Xiao, GUO Ning
Published: (2023-08-01)

Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end‐stage of renal disease
by: Seonhwa Lee, et al.
Published: (2020-06-01)

Improved heart function and cardiac remodelling following sacubitril/valsartan in acute coronary syndrome with HF
by: Henan Liu, et al.
Published: (2024-04-01)

A clinical randomized trial: Effects of early application of sacubitril/valsartan on ventricular remodeling and prognosis in acute myocardial infarction patients
by: Zhengfeng Liu, et al.
Published: (2024-12-01)